UNSPSC 51313106: Levocetirizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6U5EA9RT2O, chemically known as acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- but generally known as levocetirizine, which bears US NIH Compound Identifier 1549000. European Medicines Agency schedules Levocetirizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08467MIG.

UNSPSC 51313106 Levocetirizine is a Commodity code that appears in state and local procurement activity, but the recent opportunities posted under it do not align with the code's nominal scope. The three most recent state and local solicitations tagged to this code — covering naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative request for information (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance) — address pharmaceutical supply, pharmacy benefit management, and drug distribution broadly, rather than levocetirizine specifically or antihistamines as a product category. The mismatch suggests either a cataloging error in the state or local procurement system or a use of the code as a broad catch-all for pharmaceutical and related health-supply procurements rather than as a discrete commodity identifier.

The issuing bodies reflect a mix of county health departments, state health agencies, and cooperative purchasing consortia. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023) targets quarterly deliveries to a county community health facility with annual volumes of 1,900 units of naloxone and 800 deactivation systems; the Texas HHS Commission's RFI (posted April 3, 2026) is exploratory market research into direct-to-manufacturer pharmacy contracts; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (due March 26, 2026) seeks manufacturers of generic pharmaceuticals and OTC products for distribution across multiple state and local government entities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.). Recent activity spans Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing. The code shows little focused activity aligned to levocetirizine procurement and does not support confident characterization of state or local demand for the specific commodity.